Note: Descriptions are shown in the official language in which they were submitted.
WO 2016/196385 PCT/US2016/034861
CERDULATIN1B FOR THE TREATMENT OF B-CELL MALIGNANCIES
FIELD
The present disclosure relates generally to methods of using cerdulatinib for
treating
hematological cancers, including B-cell malignancies and relapsed or
refractory hematological
cancers.
BACKGROUND
Tumors of the hematopoietic and lymphoid tissues or hematopoietic and lymphoid
malignancies are tumors that affect the blood, bone marrow, lymph, and
lymphatic system. As
those elements are all intimately connected through both the circulatory
system and the immune
system, a disease affecting one will often affect the others as well, making
myeloproliferation
and lymphoproliferation (and thus the leukemias and the lymphomas) closely
related and often
overlapping problems.
Hematological malignancies may derive from either of the two major blood cell
lineages:
myeloid and lymphoid cell lines. The myeloid cell line normally produces
granulocytes,
erythrocytes, thrombocyies, macrophages and mast cells; the lymphoid cell line
produces B, T,
NK and plasma cells. Lymphomas, lymphocytic leukemias, and mycloma are from
the lymphoid
line, while acute and chronic myelogenous leukemia, myelodysplastic syndromes
and
mycloproliferative diseases are myeloid in origin.
B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas arc "blood
cancers" in the lymph nodes. B-cell lymphomas include both Hodgkin's lymphomas
and most
non-llodgkin lymphomas.
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
Follicular lymphoma (FL) is a type of blood cancer. It is the most common of
the
indolent (slow-growing) non-Hodgkin's lymphomas, and the second-most-common
form of non-
Hodgkin's lymphomas overall. kis,defined as a lymphoma of follicle center B-
cells (centrocytes
and centrohlasts), which has at least a partially follicular pattern.
B-cell chronic lymphocytic leukemia (B-CLL), also known as chronic lymphoid
leukemia (CLL), is the most common type of leukemia (a type of cancer of the
white blood cells)
in achilts. CLL,affects B cell lymphocyteµ Which originate in the bone marrow,
develop in the
lymph nodes and normally fight infection by producing antibodies. CLL is a
stage of small
lymphocytic lymphoma (SLL), a type of B-cell lymphoma, which presents
primarily in the
lymph nodes. CLL and SLL are considered the same underlying disease, just with
different
appearances.
Diffuse large B-cell lymphoma (DLBCL or DLBL) is a attic& of 13 cells, a type
of white
blood cell responsible for producing antibodies. Diffuse large B-cell lymphoma
encompasses a
biologically and clinically diverse set of diseases, many of which cannot be
separated from one
another by well-defined and widely accepted criteria.
B cell receptor (BCR) mediated signalling is required for chronic lymphocytic
leukemia
(CLL) pathogenesis and drugs which target kinases within the BCR signalling
complex are
revolutionising the treatment of this disease.
Some chemotherapeutic agents employed in CUL therapy include ibrutinib
(IMBRUVICA40), which targets BTX and idelalisib (ZYDELIM), which targets
PI3K&..
However these compounds suppress the disease and are not typically curative.
Additionally, CLL
patients may develop resistance to these chemotherapeutic agents either via
mutations in BTK or
downstream signalling proteins, or other mechanisms.
Current treatment options for patients who fail standard therapies for CLL,
SLL, 13LBCL,
and FL are limited. Accordingly, there is a need for new therapies for
hematological
malignancies.
2
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
SUMMARY
Provided herein are methods of treating a hematologic cancer, or B-cell
malignancies, in
a human patient in need thereof, comprising administering to the patient a
daily dose of about 10
mg to about 75 mg of cerdulatinib ora pharmaceutically acceptable salt
thereof.
Also provided herein are methods for treating a relapsed or refractory
hematologic cancer
in a patient in need thereof, comprising administering to the patient an
effective amount of
eerdulatinib, or a pharmaceutically acceptable salt thereof.
Some embodiments provide for methods of treating a relapsed or refractory
hematologic
cancer in a patient in need thereof, comprishitadministoring to the patient an
effective amount
of cerdulatinib, or a pharmaceutically accepable it theteof, wherein:
the patient has a mutation linked to relapse and/or a resistance to a drug for
treating .a
hematological cancer, and
the effective amount of cettlUlatinib, or a pharraacentio4lly acceptable Salt
thereOtis 4,
daily dose of about 30 mg to about 80 mg Of cerittatiliflib,
In some embodiments, the hematologic cancer is Chronic Lymphoeytic
LeukemIa.('CLL),
Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), transformed
Follicular
Lymphoma (tFL), Diffuse Large B-cell Lymphoma (DLBCL), or Mantle Cell Lymphoma
(MCL).
In some embodiments, the patient in need thereof is a patient exhibiting drug
resistance to
and/or a relapsed for a hematological cancer for a number of reasons. For
example, the patient
may have a mutation linked to relapse and/or a resistance to a drug for
treating a hematological
cancer. For example, the patient may have a de117p mutation, a P53 mutation,
an ATM
mutation, a STAT mutation, a STAT 6 mutation, a C481$ STAT6 mutation, a
mutation
associated with the NOTCH pathway, a mutation associated with the Caderin
pathway, or a
combination thereof. According to some embodiments, the patient does not have
a mutation in
all of P53, BTK, and EP300.
3
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 provides a bar graph that depicts inhibition of Edu incrapondion by
PACS
analysis in a variety of DLBCL cell lines at 2 jiM of cerdulatinib at 72
hours.
Figure 2 provides a bar graph that depicts inhibition of precedent induction
of caspase 3
cleavage by FACS analysis in a variety of DLBCL cell lints at 2 M of
cerdulatinib at 72 hours.
Figure 3 provides hind paw inflammation scores (mean standard error of mean
("SEM"); y-axis; n=8 per group) are plotted over time (x-axis) while treated
with vehicle or
various dose levels of cerdulatinib. The average plasma concentrations (Cmaõ)
for each dosing
group is shown at the tight of the graph. Asterisks denote statiStica1
significant relative to vehicle
by student T test (p <0.05).
Figure 4 shows the results of the effects of ibrutinib and cerdulatinib in WT
BTK-
transfected TMD8 cells. 250 nM of ibrutinib or cerdulatinib was added into the
culture and live
cell number was counted daily for 7 days. The results shown are the mean +
standard error
("SE") of 4 replicate experiments. Open circle = diraethylsulfoxide ("DMSO");
closed circle =
ibrutinib ("IBR"); triangle = cerdulatinib ("Cetd").
Figure 5 shows the effects of ibrutinib and cerdulatinib in BTKG481s -
transfected TMD8
cells. 250 nM of ibrutinavor cerdulatinib was added into the culture and live
cell number was
counted daily for 7 days: The results shown are the mean + SE of 4 replicate
experiments. Open
circle = dinaethylsulfoXide ("DIVISO"); closed circle = ibrutinib ("IBR");
triangle = cerdulatinib
("Cerd").
Figure 6 shows that CLL cells with unmutated ("UM") IGHV (N=33) are more
sensitive
to cerdulatinib than.IGHV mutated ("M") CLL (N=27). Data was analyzed with
Student T test,
mean-i-SE of IC50 are plotted. P=0.0395,
Figure' 7 shows cerdulatinib sensitivity of CLL cells with different
cytogenetic
abnormalities. Case numbers for each subgroup are indicated. Data was analyzed
by ANOVA
testometm+SE of IC50 are plotted.*, P4L05.
4
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
DETAILED DESCRIPTION
1. Definitions
Unless defined otherwise, all technical and scientific terms used herein have
the same
meaning as commonly understood by one of ordinary skill in the art to which
this disclosure
belongs. As used herein the following wills have the following meanings.
It must be noted that as used herein and in the appended claims, the singular
forms "a",
"an", and "the" include plural referents unless the context clearly dictates
otherwise. Thus, for
example, reference to "an agent" includes a plurality of agents.
As used herein, the term "compriSiog" or "comprises' is intended to mean that
the
.. compositions and methods include the recited elements, but not excluding
others. "Consisting
essentially of' when used to define compositions and methods, shall mean
excluding other
elements of any essential significance to the combination for the stated
purpose. Thus, a
composition consisting essentially of the elements as defined herein would not
exclude other
materials or steps that do not materially affect the basic and novel
characteristic(s) chivied.
"Consisting of" shall mean excluding more than trace elements of other
ingredients and
substantial method steps. Embodiments defined by each of these transition
terms are within the
scope of this disclosure.
The term "about" when used before a numerical designation, e.g., temperature,
time,
amount, and concentration, including range, indicates approximations which may
vary by (+) or
(¨) 10%, 5% or 1%.
As used herein, the term "pharmaceutically accepta.ble salt" refers to any
acid or base
addition salt whose counter-ions are non-toxic to the patient in
pharmaceutical doses of the salts.
A host of pharniaceutically acceptable salts are well known in the
pharmaceutical field. If
pharmaceutically acceptable salts of the compounds of this disclosure are
utilized in these
compositions, those salts are preferably derived from inorganic or organic
acids and bases.
Included among such acid salts are the following: acetate, adipate, alginate,
aspartate, benzoate,
benzene sulfonate, bisulfate.; butyrate, citrate, camphorate, camphor
sulfonate,
cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,
fumarate, lucoheptanoate,
5
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
glycerophosphate, hemisulfate, heptanoate. hexanoate, hydrochloride,
hydrobmmide,
hydroiodide, 2-hydmxyethanesulfonate, lactate, maleate, methanesulfonate, 2-
naphthalenestdfonate, nicotinate, oxalate, pamoate, pectinate, persuifate, 3-
phenyl-propionate,
picratc, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate,
undecanoatc, hydrohal ides
(e.g., hydrochlorides .anct hydrobromides), sulphates, phosphates, nitrates,
sulphamates,
malonates, salicylates, tnethylene-bis-b-hydroxynaphthoates, gentisates,
isethionates, di-p-
toluoyhartrates, ethanesulphonates, cyclohexylsulphatnates, quinates, and the
like.
Pharmaceutically acceptable base addition salts include, without limitation,
those derived from
alkali or alkaline earth metal bases or conventional organic bases, such as
triethylamine,
pyridine, piperidine, morpholine, N-methylmorpholine, artunonium salts, alkali
metal salts, such
as sodium and potassium salts, alkaline earth metal salts, such as calcium and
magnesium salts,
salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-
glucamine, and salts with
amino acids such as arginine, lysine, and so forth.
Furthermore, the basic nitrogen-containing groups may be quaternized with
agents like
lower alkyl halides, such as methyl, ethyl, propyl and butyl chlorides,
bromides and iodides;
dialkyl sulfates, such as dimethyll, diethyl, dibUtyl and diamyl sulfates,
long chain halides, such
as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides;
aralkyl halides, such as
benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible
products are
thereby obtained.
"Prodrug"s of cerdulatinib or other compounds described herein are also
encompassed
and are those compounds that readily undergo chemical changes under
physiological conditions
to provide the -compounds of the present disclosure. Additionally, prodrugs
can be converted to
the compounds of the present disclosure by chemical or biochemical methods in
an ex vivo
environment. For example, prodrugs can be slowly converted to the compounds of
the present
disclosure when placed in a transdermal patch reservoir with a suitable enzyme
or chemical
reagent. Prodrugs.are frequently, but not necessarily, pharmacologically
inactive until converted
into the active drug. Prodrugs are typically obtained by masking a functional
group in the drug
believed to be in part required for activity with a progroup (defined below)
to form a promoiety
which undergoes a transformation, such as cleavage, under the specified
conditions of use to
release the functional group, and hence the active drug. The cleavage of the
promoiety may
6
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
proceed spontaneously, such as by way of a hydrolysis reaction, or it may be
catalyzed or
induced by another agent, such as by an enzyme, by light, by acid or base, or
by change of or
exposure to a physical or environmental parameter, such as achange
ofteMperature. The agent
may be endogenous to the conditions of use, such as an enzyme present in the
cells to which the
prodrug is administered or the acidic conditions of the stomach, or it may be
supplied
exogenously.
"Progroup" refers to a type of protecting group that, when used to mask a
functional
group within an active drug to form a promthety, converts the drug into a
prodrug. Progroups are
typically attached to the functional group of the drug via bonds that are
cleavable under specified
conditions of use. Thus, a progroup is that portion of a promoiety that
cleaves to release the
functional group under the specified conditions of -use. As a. Specific
example, an amide
promoiety of the formula ¨NH¨C(0)0-13 comprises the progroup --C(0)013.
A wide variety of progroups, as well as the resultant promoieties, suitable
for masking
functional groups in the compounds described herein to yield prodrugs are well-
known in the art.
For example, an amino functional group may be masked as an amide, carbamate,
imine, urea,
phosphenyl, phosphoryl or sulfcnyl promoiety, which may be hydrolyzed in vivo
to provide the
amino group. The disclosure includes those esters and acyl groups known in the
art for
modifying the solubility or hydrolysis characteristics for use as sustained-
release or prodrng
formulations. Other specific examples of suitable progroups and their
respective promoieties will
be apparent to those of skill in the art.
As used herein, an -inhibitor" refers to an agent or molecule that inhibits or
binds to,
partially or totally blocks stimulation or activity, decreases, closes,
prevents, delays activation or
enzymatic activity, inactivates, desensitizes, or down regulates the activity
of a receptor.
The term "pharmaceutically acceptable carrier or excipient" means a carrier or
excipient that is useful in preparing a pharmaceutical composition that is
generally safe, non-
toxic and neither biologically nor otherwise undesirable, and includes a
carrier or excipient that
is acceptable for veterinary use as well as human pharmaceutical use. A
"pharmaceutically
acceptable carrier or excipient" as used herein includes both one and more
than one such carrier
or excipient.
7
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
The term "administering" refers to oral administration, administration as a
suppository,
topical contact, intravenous, intraperitoneal, intniftsen.104.intralesional,
intranasal or
subcutaneous administration, or the implantation of a slow-reiease device
e.g., a mini-osmotic
pump, to a subject. Administration is by any routel=including parenteral and
transmucosal (e.g.,
buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, -or
transdermal). Parenteral
administration includes, e.g., intraVOPous, intramuscular, intra-arteriole,
intradennal,
subeutaneout, intrapetitoneal, intraventricular, and intracranial. Other modes
of delivery
include, but are not limited toõ the use Of liposomal formulations,
intravenous infusion,
transdermal patche.s, etc.
`Patient" refers to human and non-human animals, espe.cially mammals. Examples
of
patients include, but are not limited to, humans, cows, dogs, cats, goats,
sheep, pigs and rabbits.
The terms "treat," "treating," "treatment," and grammatical variations thereof
as used
herein, includes partially or completely delaying, alleviating , mitigating or
reducing the intensity
of one or more attendant symptoms of a disorder or condition and/or
alleviating, mitigating or
impeding one or more causes of a disorder or condition. Treatments as
described herein may be
applied preventively, prophylactically, pallatively or remedially.
The terms "prevent," "preventing," -prevention," and grammatical variations
thereof as
used herein, refers to a method of partially or completely delaying or
precluding the onset or
recurrence of a disorder or condition and/or one or mom of its attendant
symptoms or barring a
subject from acquiring or reacquiring a disorder or condition or reducing a
subject's risk of
acquiring or requiring a disorder or condition or one or more of its attendant
symptoms.
In the present context, the term "therapeutically effective" or "effective
amount"
indicates that a compound or material or amount of the compound or material
when administered
is sufficient or effective to prevent, alleviate, or ameliorate one or more
symptoms of a disease,
disorder or medical condition being treated, and/or to prolong the survival of
the subject being
treated. The therapeutically effective amount will vary depending on the
compound, the disease,
disorder or condition and its severity and the age, weight, etc., of the
mammal to be treated. The
dosage can be conveniently administered, e.g., in divided doses up to four
times a day or in
sustained-release form.
8
Date Recue/Date Received 2022-11-18
WO 2016/196385
PCT/US2016/034861
As used herein, "daily dose" refers to a total amount of a therapeutic
substance that is to
be taken within 24 hours.
The methods and compositions described herein will typically be used in
therapy for
human subjects. However, they may also be used to treat similar or identical
indications in other
.. animal subjects. In this context, the terms 4subject," "animal subject,"
and the like refer to
human and non-human vertebrates, e.g. mammals, such as non-human primates,
sports and
commercial animals, e.g., equines, bovines, porcines, vines, rodents, and
pets, e.g., canines and
felines.
2. 144044 of Use
Malignant B cells receive survival signals that originate from a tumor itself
as well as
from non-tumor cells residing in the microenvironment. The B cell antigen
receptor (BCR) and
cytokine receptors contribute to survival.
Subsets of B cell lymphomas demonstratea reliance on BCR and/or cytokine
JAK/STAT
Signaling for survival. SYK is positioned upstream Of BTK, 'MKS, and PLC3f2 on
the pa.
signaling pathway, making it a potential therapeutic target. Additional
survival support appears
to be mediated by cytokine-induced JAK/STAT pathways, which can be activated
by tumor
autocrine signaling loops, or by pro-inflammatory cytokines originating from
non-tumor
infiltrating leukocytes present in the tumor microenvironment.
Increased serturi4WentratiOn$ ofseveraloyokina. are observed in CI.,L and non-
Hodgkin's lymphoma ("NHL"), and predict a more aggressive disease progression.
The source
of these cytolcines may be deiived from the tumor itself in an autocrine
stimulation fashion, or
from non-tumor leukocytes which have mounted an ineffective immune response
within the
tumor microenvironment. Experimentally, IL4 has been shown to promote the
survival of CLL
B-cells in culture and protect them from death by treatment with fludarabine
and chlorarnbucil.
The mechanism underlying this survival support appears to be cytokine-induced
up-regulation of
BCL2 family members.
The importance of B cell receptor (BCR) mediated signaling in the pathogenesis
of
chronic lymphocytic leukaemia (CLL) has become even more apparent in recent
years, and drugs
9
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
which target kinases within the BCR signaling complex are revolutionizing the
treatment of this
disease. Recently approved agents for relapsed/refractory CLLinclude ibrutinib
(13TK inhibitor)
and idelalisib (P131(45 inhibitor). To date, these compounds have notroved
curative, which may
in part be mediated by signals from the tumor. Importantly, a proportion of
patients are
developing resistance to these new agents, either through mutations in BTK or
PLC), for
ibmtinib or because of as yet unknown mechanisms. Spleen tyrosine kinase (SYK)
belongs to
the SYK/ZAP70 family of non-receptor kinases and plays a central role in the
transmission of
activating signals downstream of the BCR, chemoldne and integrin receptors
within B cells, and
remains an intriguing target for the treatment of certain B cell malignancies
and autoimmune
disease.
CLL cells are dependent upon signals from various cells constituting the
microenvironment. IL-4 signals in lymphocytes are derived predominantly
through the type 1 IL-
4 receptor (IL-4R) via Janus protein tyrosine kinases JAKI and JAK3 resulting
in
phosphorylation of STAT6 (pSTAT6).
Current treatment options for patients who fail standard therapies for chronic
lymphocytic leukemia (CLL). small lymphocytie lymphoma (SLL). and follicular
lymphoma
(FL) are limited.
Provided herein are methods of treating a hematological cancer by
administration of
cerdulatinib. Ceniulatinib is a small molecule, ATP-competitive, reversible
inhibitor of both
SYK and JAK family members. Cerdulatinib, which has been described previously
OM e.g.,
U.S. 8,138,339), has a chemical name 4-(cyclopropylamino)-2-(4-(4-
(ethylsulfortyl)piperazin-1-
y1)phenylamino)pyrimidine-5-carboxamide, and has the formula:
H3C0
11.0
A,..NH 0
L,)L
N NH2
N Nõõ..
In embodiments described herein, cerdulatinib may also refer to a
pharmaceutically
acceptable salt or prodrug thereof.
Date Recue/Date Received 2022-11-18
WO 2016/196385
PCT/US2016/034861
It is contemplated that cerdulatinib may be useful for heavily pre-treated
patients and/or
relapse/refractory hematological cancers, including but not limited to eLL,
FL, NHL, and
DLBCL. CenthiatinibldsoindUces apoptosis in primaryal, with putferential
activity in cases
of poor prognosis such as unmutated IGHV, high CD49d, ZAP-70, or surface igM
expression.
Provided herein are methods of treating a hematologic cancer in a human
patient in need
thereof, comprising administering to the patient a daily dose of about 10 mg
to about 75 mg of
cerdulatinib, or a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition
comprising a daily dose of about 10 mg to about 75 mg of cerdulatinib, or a
pharmaceutically
acceptable salt thereof, and at least one pharmaceutically acceptable
excipient or canier.
Also provided herein are methods for treating a relapsed or refractory
hematologic cancer
in a patient in tieed thereof, comprising administering to the patient an
effective amount of
cerdulatinib, or a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition
comprising a daily dose of about 10 mg to about 75 ing of cerdulatinib, or a
pharmaceutically
acceptable salt thereof, and at least one pharmaceutically acceptable
excipient or carrier.
Some embodiments provide for methods of treating .a relapsed or refractory
hematologic
cancer in a patient in need thereof, comprising administering to the patient
an effective amount
of cerdulatinib, or a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition
comprising an effective amount of cerdulatinib, or a pharmaceutically
acceptable salt thereof,
and at least one pharmaceutically acceptable excipient or carrier, wherein:
the effective amount of cerdulatinib, or a pharmaceutically acceptable salt
the,reof, is a
daily dose of about 30 mg to about 80 mg of cerdulatinib.
Some embodiments provide for methods of treating a relapsed or refractory
hematologic
cancer in a patient in need thereof, comprising administering to the patient
an effective amount
of cerdulatinib, or a pharmaceutically acceptable salt thereof, or a
pharmaceutical composition
comprising an effective amount of cerdulatinib, or a pharmaceutically
acceptable salt thereof,
and at least one pharmaceutically acceptable excipient or carrier, wherein:
the patient lima mutation linked to relapse and/Or a resistance to a drug for
treating a
hematological cancer; and
11
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
the effective amount of cerdulatinib, or a pharmaceutically acceptable salt
thereof, is a
daily dose of about 30 mg to about 80 mg of cerdulatinib.
Some embodiments provided herein are related to methods of treating a patient
suffering
from one or more of a B-cell non-Hodgkin's lymphoma (NIIL), chronic
lymphocytic leukemia
=5 ((s.ji ), follicular lymphoma (FL), diffuse large B-cell lymphoma
(DLBCL) or other transformed
FL,
In some embodiments, the patient suffers one or more of B-cell malignancy,
chronic
lymphocytic leukemia (CLL), follicular lymphoma (FL), or transformed FL.
In some embodiments, the patient suffers from an advaneed malignancy.
In some embodiments, the patient has relapsed or not responded to a prior
chemotherapy.
In some embodiments, the patient has failed at least two prior therapies. In
some embodiments,
the patient has failed at least one prior therapy.
In some embodiments, the patient has a B cell Malignancy. In some embodiments,
the
methods provided herein are used to treat a heinatological cancer such as
chronic lymphocytic
11 16ukernia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma
(FL)k transformed
follicular lymphoma (tFL), diffuse large 13-cell lymphoma (DLBCL), and/or
mantlevell
lymphoma (MCL). In some embodiments, the methods provided herein are used to
treat a
hematological cancer such as non-Hodgkin's lymphoma (NHL), chronic
lyrnphocytic leukemia
(CLL), Small lymphocytic lyrnphoraa (SLL), follieular lyniptarma (PL),
transformed follicular
26 lymphoma (tFL), diffuse large B-cell lymphoma (DLBM), and/or mantle
cellnyt4thcittia
(MCL).
According to some embodiments, the hematological cancer is CLL. According to
some
eMbodlments, the hematological cancer is DLBCL. According to some embodiments,
the
hematological cancer is FL. According to some embodhnents, the hematological
cancer is SLL.
25 According to some embodiments, the hematological cancer is NHL.
According to some
embodiments, the hematological cancer is tFL. According to some embodiments,
the
hematological cancer is MCL.
12
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
Some chemotherapeutic agents suffer from drug resistance in a patient, for
example, due
to BCR 1L-4 mediated signalling and/or BCR activation pathways, which are
protective of
hematological cancer. According to embodiMents of the present disclosure,
cerdulatinib can
overcome these protective mechanisms, which lead to drug resistance.
In some embodiments, the patient in need thereof is a patient exhibiting drug
resistance
to, and/or a relapsed for, of a hematological cancer for a number of reasons.
For example, the
patient may have a mutation linked to relapse and/or a resistance to a drug
for treating a
hematological Cancer. For example, the patient may have a de117p mutation, a
P53 mutation, an
ATM mutation, a STAT mutation, a STAT 6 mutation, a C481S STAT6 mutation, a
mutation
associated with the NOTCH pathway, or a mutation associated with the Caderin
pathway.
In some embodiments, the patient may have a S86A mutationlit.STAT.
In some embodiments, the patient may have a de117p mutation, dell lq mutation,
a P53
mutation, an ATM mutation, a STAT mutation, a STAT 6 mutation, a C481S STAT6
mutation, a
mutation associated with ,the NOTCH pathway, a mutation associated with the
Caderin pathway,
or a combination thereof.
According to some embodiments, the patient does not have a mutation in each of
P53,
BTK, and EP300.
In some embodiments, the patient has a MYD88 mutation, a CARD11 mutation, or a
A20
mutation. In some embodiments, tile pilaw- has high-risk genetic abnormalities
including
dell 1 q, trisorny 12, and dell-/p. In some embodiments, the patient has a
dell7p mutation. In
some embodiments, the patient has a dell lq mutation.
In some embodiments, the patient has a BTK mutation.
hi some embodiments, the patient may have a poor prognosis such as unmutated
IGHV,
high CD49d, ZAP-70, or surfaCe IgM expression.
In some embodiments, the patient has resistance to a drug, which is not
cerdulatinib.
Non-limiting examples of these drugs arc an anti-CD20 antibody, a BCL-2
inhibitor, a BTK
inhibitor, a P13Ko inhibitor, rituximab, a platinum-based drug, an
antimetabolite, ibrutinib,
13
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
iclelalisib, fludararbine (fludara.bine phosphate, PLUDARA0), anthracyclincs.
a BCR pathway
inhibitor, ABT-199 (Venetoelax), or another chemotherapeutic agent used for
treating a
hematologic cancer. Other non-limiting maimples of chemotherapeutic
agentsinclude alkylating
agents, cytoskeletal disruptors, cpothiolones, histone dcacctylase inhibitors,
inhibitors of
topoisomerase 1, inhibitors of topoisomerase IL nucleotide analogs and
precursor analogs,
antibiotics, platinum-based agents, redo:Ads, vinca alkaloids, or a
combination thereof.
In some embodiments, the patient has resistance to an anti-CD20 antibody, a
BCL-2
inhibitor, a BTK inhibitor, a P13K8 inhibitor, a platinum-based drug, an
antimetabolite, an
arithracycline,a BCR pathway inhibitor, or another chemotherapeutic agent used
for treating a
hematologic cancer. In some embodiments, file patient has resistance to a drug
selected from the
group consisting of ABT-199 (venetoclax), rituximab, ibrutinib, idelalisib,
and fludararbine
(ludarabine phosphate, FLUDARA6). In some embodiments, the patient has
resistance to
ibrutinib.
In some embodiments, the patient was previously administered a drug for
treating a
hematological cancer. Non-limiting examples the drug include an alkylating
agent, an anti-CD20
antibody, .a BCL-2 inhibitor, a BTK inhibitor; a PBXS inhibitor, rituximab, a
platinum-based
drug, an antimetabolite, ibrutinib, idelalisib, fludararbine (fludarabine
phosphate, FLUDARAe),
antbracyclines, a BCR pathway inhibitor, ABT-199 (venetoelax), and other
agents used for
treating a hematologic cancer. Other non-limiting examples of chemotherapeutic
agents include
cytoskeletal disruptors, epothiolones, histone deaeetylase inhibitors,
inhibitors of topoisomerase
L inhibitors of topoisomerase II, nucleotide analogs and precursor analogs,
antibiotics, platinum-
based agents, retinoids, vinca alkaloids, or a combination thereof.
In some embodiments, the patient was previously administere.d a drug selected
from the
group consisting of an alkylating agent, an anti-CD20 antibody, a BC1,2
inhibitor, a BTK
inhibitor, a P13K8 inhibitor, a platinum-based drug, an antinaetabolite, an
funahracycline, a BCR
pathway inhibitor, and another chenaotherapeutic agent used for treating a
hematologic cancer. In
some embodiments, the patient Wks previously adittinistered a drug selected
from the group
consisting of venetoclax, rituxirnab, ibrutinib, idelalisib, and fludararbine.
In some embodiments,
the drug is R-CHOP (Rituximab; Cyclophosphamide; Doxorubicin hydrochloride;
Oncovin
14
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
(vincristine); Prednisone). In some embodiments, the drug is R-CVP (Rituximab;
Cyclophosphamide; Vinctistine; Prednisone). In sdrassembodiments, the drug is
bevacizumab. In
some embodiments, the drug is a combination of fludarabine and ritnximab, a
combination of
bendamustinc and rituximab, or a combination of bevacizumab and rituximab.
In certain embodiments, the patient -is 60 years or older and relapsed after a
first line
cancer therapy. In certain embodiments, the patient is 18 years or older and
is relapsed or
refractory after a second line cancer therapy. In certain embodiments, the
patient is 60 years or
older and is primary refractory to a first line cancer therapy. In certain
embodiments, the patient
is 70 years or older and is previously untreated. In certain embodiments, the
patient is 70 years or
older and is ineligible and/or unlikely to benefit from cancer therapy.
The amounts of various compounds to be administered can be determined by
standard
procedures taking into account factors such as the compound IC50, the
biological half-life of the
compound, the age, size, and weight of the subject, and the indication being
treated. The
importance of these and other factors are well known to those of ordinary
skill in the
art. Generally, a dose will be between about 0.01 and 50 mg/kg, or 0.1 and 20
mg/kg of the
subject being treated. Multiple doses may be used.
In some embodiments, methods of treating a relapsed or refractory hematologic
cancer in
a human patient in need thereof comprises administering to the patient a daily
dose of about 10
mg to about 75 mg-of cerdulatinib or a pharmaceutically acceptable salt
thereof or a
phannaceutical composition comprising a daily dose of about 10 rag to about 75
mg of
cerdulatinib or a phartnaceutically acceptable salt thereof, and at least one
pharmaceutically
acceptable carrier or excipient.
In some embodiments, methods of treating a relapsed or refractory hematologic
cancer in
a human patient in need thereof comprise administering to the patient a twice
daily a dose of
about 45 mg of cerdulatinib or a pharmaceutically acceptable salt thereof.
In some embodiments, methods of treating a relapsed or refractory hematologic
cancer in
a human patient in need thereof -comprise administering to the patient a twice
daily a dose of
about 35 mg of cerdulatinib or apharmaceutieally acceptable salt thereof.
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
In some embodiments provided herein, the daily dose of cerdulatinib is about
10 mg to
about 15 mg. In some embodiments provided herein, the daily dose of
cerdulatinib is about 25
mg toebOut 45 mg. hi some embodiments, the-daily doseof cerdulatinib is about
15 mg, 30 mg,
45 mg, or 50 mg.
In some embodiments, the daily dose of cerdulatinib is about 15 Mg, about 20
mg, about
25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg,
about55 mg, abotit
60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 90 mg, about
95 trig, about
100 mg, about 105 mg, or about 110 mg. In some embodiments, the daily dose of
cerdulatinib is
about 90 mg, In some embodiments, the daily dose of cerdulatinib is about 70
mg. In some
.. embodiments, the daily dose of cerdulatinib is administered twice daily at
about 35 Mg per dose.
In some embodiments, the administration of cerdulatinib is once daily. In some
embodiments, the administration is twice cially, In some embodiments, the
administration is three
times daily.
In certain embodiments, the therapeutically effective amount of cerdulatinib
used in the
.. methods Provided herein is at least about 10 mg per day. In one embodiment,
the therapeutically
effective amount of cerdulatinib is at least about 10,20, 30,40, or 50 mg per
dosage, In one
embodiment, the therapeutically effective amount of cerdulatinib is at least
about 10, 20, 30, 40,
50, 60, 70, 80, 90 or 100 mg per day.
In one embodiment, the therapeutically effective amount of certhilatiiiib is
at 'least 30 mg,
35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, or 65 mg per day. In one embodiment,
the
therapeutically effective amount of cerdulatinib is At least about 15 mg, 20
mg, 25 mg, 30 mg, or
35 mg and is administered twice daily.
In certain embodiments, the therapeutically Ofective amount oteerdulatinib is
no more
than about 500, 400, 300, 200, 150, 120, or 100 mg per day. In one embodiment,
the
therapeutically effective amount of cerdulatinib is no more than about 300,
200, 150, 120, 100,
90, 80, 70, 60, 55 or 50 mg per dosage.
In certain embodiments, the therapeutically effective amount- of cerdulatinib
is no more
than about 100 mg, 95 tug, 90 mg, 85 nag, 80 mg, or 75 mg per day. In certain
embodiments, the
16
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
therapeutically effective amount of cerdulatinib is no more than 45 mg, 40 mg,
35 mg. or 30 mg
and is administered twice daily.
In one embodiment, the therapeutically effective amount of cerdulatinib,
whether alone
or in combination with another agent, is administered at from about 10 mg to
200.mg, from
about 25 mg to 150 mg, from about 50 to 120 mg, from about 80 to 100 mg a day.
In one embodiment, the therapeutically effective amount of cerdulatinib,
whether alone
or in combination with another agent, is 25 mg to 120 mg daily. In some
emboclirnents, the
effective amount of cerdulatinib is 25 mg to 50 mg twice daily.
In one embodiment, the therapentically effective amount cerdulatinib, whether
alone or in
combination with another agent, is administered at from about 10 mg to 150 mg,
from about 25
mg to 120 mg, from about 30 to 80 mg, from about 40 to 50 mg a dosage, once
=or twice a day. In
certain embodiments, the cerdulatinib, whether alone or in combination with
another agent, is
administered once, twice, three times, or four times a day.
In one embodiment, the cerdulatinib, whether alone or in combination with
another agent,
is administered from about 30 mg to about 80 mg once a day. In one
'embodiment, the
cerdulatinib, whether alone or in combination with another agent, is
administered from about 15
mg to about 40 mg twice a day.
In one embodiment, 45 mg of eerdulatinib, whether alone or in combination with
another
agent, is administered twice daily. In one embodiment, 35 mg of cerdulatinib,
whether alone or
in combination with another agent, is administered twice daily.
In some embodiments, the effective amount of cerdulatinib, or a
pharmaceutically
acceptable salt thereof, is about 40 mg to about 50 mg administered twice
daily.
In some embodiments, the effective amount of cerdulatinib, Or a
pluurtrificeutically
acceptable salt thereof, is about 30 mg to about 40 mg administered twice
daily.
In another embodiment, the present disclosure provides a method of treating a
cancer ill a
subject in need thereof by administering to the subject an effective amount of
a composition
comprising cerdulatinib in combination with one or more other therapies or
medical procedures
17
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
effective in treating the cancer. Other therapies or medical procedures
include suitable anticancer
therapy (e.g. drug therapy, vaccine therapy, gene therapy, photodynamic
therapy) or medical
procedure (e.g. surgery, radiation treatment, hyperthermia heating, bone
marrow or stem cell
transplant). In one embodiment, the one or more suitable anticancer therapies
or medical
procedures is selected from treatment with a chemotherapeutic agent (e.g.
chemotherapeutic
drug), radiation treatment (e.g. x-ray, -ray, or electron, proton, neutron, or
particle beam),
hyperthermia heating (e.g. microwave, ultrasound, radiofrequency ablation),
Vaccine therapy
(e.g. AFP gene hepatocellular carcinoma vaccine, AFP adenoviral vector
vaccine, AG-858,
allogeneic GM-CSF-secretion breast cancer vaccine, dendritic cell peptide
vaccines), gene
therapy (e.g. Ad5CMV-p53 vector, adenovector encoding MDA7, adenovirus 5-tumor
necrosis
factor alpha), photodynamic therapy (e.g. aminolevulinic acid, motexatin
lutetium), surgery, or
hone marrow and stem cell transplantation.
3. Pharmaceutical compositions and kits
Some embodiments provided herein are directed to pharmaceutical compositions
comprising an effective amount of cerdulatinib and at least one
pharmaceutically acceptable
carrier or excipient.
Carriers or excipients can be used to produce compositions.. Thavarriert or
excipients
can be chosen to facilitate administration of the compound, such as
cerdulatinib. Examples of
carriers include calcium carbonate, calcium phosphate, various sugars such as
lactose, glucose,
or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable
oils, polyethylene glycols
and physiologically compatible solvents. Examples of physiologically
compatible solvents
include sterile solutions of water for injection (WFI), saline solution, and
dextrose.
Suitable dosage forms. in part, depend upon the use or the route of
administration, for
example, oral, transdermal, tnmsmucosal, inhalant, or by injection
(parenteral). Such dosage
forms should allow the compound to reach target cells. Other factors are well
known in the art,
and include considerations such as toxicity and dosage forms that retard the
compound or
composition from exerting its effects. Techniques and formulations generally
may he found in
The Science and Practice of Pharmacy, 21 edition, Lippincott, Williams and
Wilkins,
Philadelphia, PA. 2005.
18
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
Cerdulatinib can be administered by different routes including intravenous,
intiVeritoneal, subcutaneous, intramuscular, oral, transmucosal, rectal,
transdermal, or
inhakilit, in some embodiments, cerdulatinib can be administered by oral
administration. For
oral. administration, for example, cerdulatinib can be formulated into
conventional oral dosage
forum such as capsules, tablets, and liquid preparations such as syrups,
elixirs4 and concentrated
&Vs.
For inhalants, cerdulatinib may be fommlated as dry powder or a suitable
solution,
suspension, or aerosol. Powders and solutions may be formulated with suitable
additives known
in the art. For example, powders may include a suitable powder base such as
lactose or starch,
and solutions may comprise propylene glycol, sterile water, ethanol, sodium
chloride and other
additives, such as acid, alkali and buffer salts. Such solutions or
suspensions may be
administered by inhaling via spray, pump, atomizer, or nebulizer, and the
like. Cerdulatinib may
also be used in combination with other inhaled therapies, for example
corticosteroids such 48
fluticasone propionate, beclomethasone dipropionate, triamcinolone acetonide,
budesonide, and
mometasone furoate; beta agonists such as albuterol, salmeterol, and
formoterol; anticholinergic
agents such as ipratropium bromide or tiotropium; vasodilators such as
treprostinal and iloprost;
enzymes such as DNAase; therapeutic proteins; immunoglobulin antibodies; an
oligonucleotide,
such as single or double stranded DNA or RNA, siRNA; antibiotics such as
tohramycin;
muscarinic receptor antagonists; leukotriene antagonists; cytOkine
antagonists; protease
inhibitors; cromolyn sodium; nedocril sodium; and sodium cromoglycatc.
Pharmaceutical preparations for oral use can be obtained, for example, by
combining
cerdulatinib with solid excipients, optionally grinding a resulting mixture,
and processing the
mixture of granules, after adding suitable auxiliaries, if desired, to obtain
tablets or dragee
cores, Suitable excipients are, in particular, fillers such as sugars,
including lactose, sucrose,
mannitol, or sorbitol; cellulose preparations, for example, maize starch,
wheat starch, rice starch,
potato starch, gelatin, gum tragacanth, methyl eelluktse, hydroxypropylrnethyl-
cellulose, sodium
carboxymethylcellulose (CMC), and/Or polyvinylprrolidone (PVP: povidone). If
desired,
disintegrating agents may be added, such as the cross-linked
polyvinylpynolidone, agar, or
alginic acid, or a salt thereof such as sodium alginate.
19
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
Dragee cores are provided with suitable coatings. For this purpose,
concentrated sugar
solutions may be used, which may optionally contthn, for example, gum arable,
talc, poly-
vinylpyrrolidone, carbopol gel, polyethyleite glycol (PEG), and/or titanium
dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures. Dye-stuffs or
pigments maybe
=5 added to the tablets or dragee coatings for identification or to
characterize different combinations
of active compound doses.
Pharmaceutical preparations that can be used orally include push-fit capsules
made of
gelatin (lelcaps"), as well as soft, sealed capsules made of gelatin, and a
plasticizer, such as
glycerol or sorbitol. The push-fit capsules can contain the active ingredients
in admixture with
filler such as lactose, binders such as starches, and/or lubricants such as
talc or magnesium
stearate and, optionally, stabilizers. In soft capsules, cerdulatinib may be
dissolved or suspended
in suitable liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycols (pgas). In
addition, stabilizers may be added.
Alternatively, injection (parenteral administration) may be used, e.g.,
intramuscular,
intravenous, intraperitoneal, and/or subcutaneous. For injection, cerdulatinib
is formulated in
sterile liquid solutions, such as in physiologically compatible buffers or
solutions, such as saline
solution, Hank's solution, or Ringer's solution. In addition, cerdulatinib may
be formulated in
solid form and redissolved or suspended immediately prior to use. Lyophilized
forms can also
be produced.
Administration can also be by transmucosal, topical, transdermal, or inhalant
means. For
transmucosal, topical or transdermal administration, penetrants appropriate to
the barrier to be
permeated are used in the formulation. Such penetrants are generally known in
the art, and
include, for example, for transrnucosal administration,. bile salts and
fitsidic acid derivatives. In
addition, detergents may be used to facilitate permeation. Transmucosal
administration, for
example, may be through nasal sprays or suppositories (rectal or vaginal).
The topiCal compositions of this disclosure are formulated as oils, creams,
lotions, ointments,
and the like by choice of appropriate carriers known in the art. Suitable
carriers include
vegetable or Mineral oils, white petrolatum (white soft paraffin), branched
chain fats or oils,
animal fats and high molecular weight alcohol (greater than C12). In another
embodiment, the
carriers arc those in which the active ingredient is soluble. Emulsifiers,
stabilizers, humectants
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
and antioxidants may also be included as well as agents imparting color or
fragrance, if
desired. Creams for topical application are formulated from-a-Mature of
mineral oil, self-
emulsifying beeswax and water in which mixture the active ingredient,
dissolved in a small
amount solvent (e.g. an oil), is admixed. Additionally, administration by
transdermal means may
=5 comprise a transdermal patch or dressing Snell as a bandage impregnated
with an active
ingredient and optionally one or mem carriers or diluents known in the art= To
be administered
in the form of a transdermal delivery 'system, the dosage administratitat Wit
Of awe, I*
continuous rather than intermittent throughout the dosage regimen.
In another embodiment, the present disclosure provides kits that include
cerdulatinib or a
pharmaceutically acceptable salt thereof or a pharmaceutical composition
thereof. In some
embodiments, the compound or composition is packaged, e.g., in a vial, bottle,
flask, which may
be further packaged, e.g., within a box, envelope, or bag; the compound or
composition is
approved by the U.S. Food and Drug Administration or similar regulatory agency
for
administration to a mammal, e.g., a human; the compound or composition is
approved for
administration to a mammal, e.g, a human, for a protein kinase mediated
disease or condition;
the kits described herein may include written instructions for use and/or
other indication that the
compound or composition is suitable or approved for administration to a
mammal, e.g., a human,
for a disease or condition as described herein, such as a hematologic cancer;
and the compound
or composition may be packaged in unit dose or single dose form, e.g., single
dose pills,
capsules, or the like.
EXAMPLES
Example 1: Preclinical Models, Clinical PK/PD, and Tumor Response
Materials and Methods
IPtifeilliCinase Assays: Performed at Millipore at a fixed concentration of
300 nl+4 ATP. A 10-
point concentration curve was used to determine IC (Inhibitory Concentration).
Human Whole Blood Assays: Inhibition of SYK- and JAK-dependent and independent
signaling
was determined by stimulating human whole blood with various agonists against
BCR and
eytokine receptors. 100 ttL aliquots olheparinized healthy human whole blood
was stimulated.as
21
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
previously described (Coffey et al, .1. of Phann. and Experimental
Therapeutics, 351:538-548,
2014), using an 8-point concentration curve to determine 1050's. Signaling and
activation
responses were determined by Fluoreseende,activated cell sorting ("FACS"). For
the clinical
trial, whole blood samples were collected prior to and after dosing. Percent
inhibition was
calculated by normalizing to the pre-dose stimulation response:
DLBCL Cell Line Viability Assays: Cell lines, purchased from ATCC, were
screened using the
CellTiter Glo (Promega) assay in 384 Wellplates using a ten-point
concentration response curve
to generate IC's. Each IC50valne-is'an average of at least four replicate
experiments.
Subsequent analysis using a FACS based caspase 3 cleavage detection kit (BD
Biosciences) and
Edu incorporation were performed.
Rat Collagen Induced Arthritis: In vivo anti-inflammatory activity of
cerdulatinib was
determindi Using the rat collagen induced arduitis model and performed exactly
as described
elsewhere (Coffey et al, J. of Pharm. and Experimental Therapeutics, 340: 350-
359,:2012).
Collagen antibody titers were determined by ELISA (R&D Systems). Steady-state
serum Cmax
was determined using liquid chromatography-tandem mass spectrometry.
Cytokine Analysis: Serum protein was analyzed by Myriad RBM (Austin, 14X)
using the Human
Inflammation Map.
Clinical Study Design. This is a Phase 1 open-label, multi-dose, dose
escalation study of
eerdulatinib in patients with relapsed/refractory CLL/SLL or B-cell NHL. Study
initiated at 15
mg QD (once daily) and dose-escalated in a 3+3 design with a 28 day safety
window. Patients
received a single dose on day 1 for 72 hour PK evaluation. Continuous dosing
was then initiated
on day 4.
Results
In healthy whole blood ex vivo spiking experiments, cerdulatinib selectively
inhibited
BCR/SYK and cytokine (IL2, IL4, IL6) JAK/STAT signaling with IC50's ranging
from 01-0.9
tiM (achieved at clinical doses of 15 mg to 40 mg), arrested inflammation
andsjointdestruction
in the rat collagen-induced arthritis model at 03 1.1M average plasma
concettration (gebfevedat
22
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
doses ?30 mg), and induced apoptosis in the majority of cell lines at 2 pM
(achieved at doses
240 mg). Plasma concentrations above 21.4M have been safely achieved in cancer
patients
following once daily oral dosing, while maintaining steady-state Cmin of -
11.tM.
Cerdulatinib potency and specificity against SYK and JAK signaling
Table 1 represents eerdulatinib 1050's against purified kinases that were
inhibited >80%
in a 270 lcinase panel screen (Millipore). Despite inhibition in enzyme
reactions, there is no
evidence of inhibition at the cellular level and/or in patients for AMPK,
JAK2, RSK2,
and RSK4.
Table 1. Purified Kinase Assays
K1NASE ICso (nM)
TYK2 0.5
MST1 4
ARKS 4
MLK1 5
FMS 5
AMPK 6
JAK2 6
JAK3 8
TB K 1 14)
=
MARX! 10
JAK1
PAR IB-a 13
TSSK 14
msT2 15
GCK 18
JNK3 18
RSK2 20
RSK4 28
23
Date Recue/Date Received 2022-11-18
0.301000$0 svo2ioO3461
SIc. 32
CHKI 42
'131:114,
FLT3
RET 105
114
Table 2 is a summary of eerdulatinib ICs in:various healthy normal:human
whcileiJlood
assays 1]s data cicm0Astrales for'SYKJAKIA,441A1WITIP *pen net
totIma*POWIOragitiOgraM4MXIarrnapathoos stevomptrablo,
Table '2. Healthy Normal Human Whole Blood Assays
CELL TYPE STIMULATION KINASE READOUT 1050 (tim)
BCR SYK CD69 0.1
BCR SYK pERK Y204 0.5
114 TAK1f4 pSTAT6 Y641
PMA PKC pERK Y2(14 >4
Basophil FeeR1 SYK CD63 0.12
*K10 pSTAT5 Y-694
¨ 1J. PSTAT6 Y641 'Oa
TCR Zap70 pERK Y204 >4
PIVIA PKC' pERK Y204 >4
IL6 JAk1/TYK2 pSTAT3 Y705 0.35
momoros :
'GMCSF JAK2 pSTAT5 Y694
Cierdulatilob is broadlEatibte WIWI 15 DLItelitalliffittfat 2 fin,
Ceniulatinib demonstrated broad anti-tumor aetivityin DI ,BCksecil lines, xela
ti VC :to
morertaxgeteci ago4s:j411,04)6,1ow:saufpn4riggslCiONO.40 o anbpLocitw
O re*011tiOnt$0 intititar$1 :PRT06330Ykinh1bitorodaa is itscribod
V5,10airs
L432.9&); jflSb1uj1óiT' MX Inhibitor (CM 4577081-0327t Van-Ur in TWO); CP-
6905*
24
Date Recue/Date Received 2022-11-18
#(01(110/19005, :)P0.0014.1931061.
(UM loWlit01; ickialtabOrg0 Nlibitrk);. II. .I- aud
.01)40rAt.ltbi,.$1:y.dit104.,
'ThOtiribibiratOro...461116101.101411taltalabIdtitatt,:ita40-00#1friticil
lithetk: Itiethoils flid.: Oki110,410.Thdlitt.
Table if
Ileso of 'Kinase Inhibitor lit 'ee11Titer 610 Assay
Cell line Cerdulatinib PRT06- Pan, CP690 Iclelallsib 1P1-145 Doxo
31111 Jalic .510
IA 1$ 0.8 50 __ tit 046
'AL .23 45 12 50 .29 21 0.22
OHL6
LY10 0.29 0.31 5.1 50 12 0.04
D11L4 14. 1..1 M);.= 2$. .12 33:
D111.5 ,01.1 0.44 1.9.: 41 L. 010 MO1
U2932 2.6 8 3.9 50 40 27 0.35
44 10, 03. .50 45 13 049:
ORLI 1.1 20: 40 50
LY7 .15 9. 34: 50 13. 25 0.14
MILS.' 3449 .34 49:, OA,
DILA: r.42 5,4 E.0' 4.2 :$0 15 5 018.
DB 14 30 21.:4 .50 42 SO' 031'
TOLEDO :64 IS. 5451 4.1 50' rg 0.44.
154 22 43 50 50 50 0.20
in a piwpt cif 15 ceJ1 Iiios.,iqpipenting widcrompt
4p0ptosi* a ao additiootterwontgelloglo .V00,pwave. en** OrniC and IAN
teibitiotivereobsereed,W4 or
ito,:wIteroas :$ cell .lines woreio.eggitivo to.$.xlc toton.
an I 'aUneWas kilativdtki JAK.Uit tidt-SYK inh hi
Thite.of The 15'tI.
Hat (DB. TOLEDO, hill RCM) miere
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
Figure 1 and Figure 2 depicts bar graphs that show the percent inhibition of
Edu
incorporation and percent induction of caspase 3 cleavage by PACS analysis,
respectively.
The above data demonstrates that cerdulatinib is broadly active against DLBCL
cell lines
at 2 M and acts predominately by inducing aPoPtosis.
Cerdulatinib Arrests AutuhlanioneVethanisms at 0.52 1.1111 C. in Rats.
Figure 3 shows data from a rat collagen induced arthritis model. Hind paw
inflammation
scores (mean SEM; y-axis; n=8 per group) are plotted over time (x-axis)
while treated with
vehicle or various dose levels of cerdulatinib. The average plasma
concentrations (Cmax) for each
dosing group is shown at the right of the graph. Asterisks denote statistical
significant relative to
vehicle by student T test (p < 0.05).
Inflammation and auto-antibody generation in rats were completely arrested at
cerdulatinib plasma concentrations of between 0.5-0.6 MM C. (corresponding to
¨ 0.3-0.4 M
Caverage). These exposures,are safely achieved in humans at the 30 mg once
daily dose, and
correspond to approximately 50% inhibition of SYK and JAK in peripheral whole
blood assays.
Clear evidence for reduction of serum 132M (and other infbmmation markers) was
observed at all
dose levels tested clinically.
Potency of SYK and JAK inhibition following oral dosing in patients.
Following oral dosing in patients, SYK and JAK pathways were inhibited with
similar
potency as was observed in healthy volunteer ex vivo spiking experiments, and
>90% inhibition
of SYK and JAK has been safely achieved for multiple cycles of therapy.
Tumor response-1* menu* by CT scan significantly correlated with percent
inhibition
of SYK and JAK signaling in patient-derived whole blood, and percent
inhibition of serum
markers of inflaMmation (e.g. 32M, CRP, 11,10, \TAW, sTNFR, CCL3).
Conclusions
Ccrdulatinib concentrations required to induce apoptosis and/or cell cycle
arrest are
variable but generally observed at 2 M. Steady-state concentrations of 1-2 04
Gni. to C. are
26
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
safely achieved at 40 mg QD. Patient tumor reductions as assessed by CT scan
significantly
correlate with % inhibition of SYK and JAK, % inhibition of several serum
inflammation
markers and is also related to cerdulatinib plasma concentration. Dose
escalation continues with
good tolerability up to 1(X) mg QD.
Based on these results, it is contemplated that cerdulatinib is useful for
treatment of B-
cell lymphomas, such as DLBCL.
Example 2: Effect of the cerdulatinib on primary human CLL cells
Cerdulatinib in 24 primary CLL samples
CLL cell isolation and cultufe: CLL cells (commercially available from ATCC)
were purified
.. using the Human B cell Enrichment Cocktail Kit (Sterncell Technologies,
Vancouver, BC,
Canada) and were stained with anti-CD5/CD19 for verification of the purity,
which was greater
than 95% for all cases. Isolated CLL cells were cultured in RPMI-1640 with 15%
fetal bovine
serum (Gibco, Grand Island, NY, USA), penicillin (100 IU), and streptomycin
(100 g/r0L), at a
density of 1x107cells/triL in the presence or absence of 2.5 ing/mL Cp0 , 100
nstin.L CD401õ, 10
ng/mL Anti-IgM stimulation was conducted with plate-bound anti-IgM (10
lig/mL). CLL
cells were stimulated with 10 neml. IL-6 (R&D Systems, Minneapolis, MN),.. to
detect the
phosphorylat ion of JAK1/JAK2 (Cell Signaling Technology, Danvers, MA) and
STAT3 (Cell
Signaling Technology, Danvers, MA, USA),
Cell 'Viability assay and IC so determination: Isaitxtedt135+/CD19+ cells from
CLL patients were
.. incubated with or without increasing concentrations of cerdulatinib (lew
nM) for 72 hours
and cell viability was measured by staining with 2 1.1g/mL propidium iodide
(PI) (Molecular
Probe), as previously described, Ten thousand events in a live cell gate were
counted by a FACS
LSR2 (BD Biosciences) and the data was normalized to the matched vehicle
control for each
specimen (100%). IC50 was then generated using the GraphPad Prism 6 program
(San Diego,
CA, USA).
Co-culture conditions: Human bone marrow stromal cell line HS-5 was obtained
from ATCC
and NK-Tert (NKTert) was kindly provided by Dr. Jan A. Burger (M.D. Anderson),
CLL cell
and stroinal cell co-culture assays were described previously (e.g. Cheng et
al., Leukemia.
27
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
2014;28(3):649-657). Briefly, stromal cells were seeded at a concentration of
5x104 cells/per
wel1.ih24-well plates and were incubated for 24 hours to -allow cells to
adhere. CLL cells were
then added to the cultuteati MI6 of 100:1 (5 x106ce11s/mL) on confluent layers
of stromal cells
in RPM! medium. CLL cells were harvested by gentle 'ripening, leaving the
adherent stromal
cell layer intact.
Prinitry CLL samples with serial diluted cerdulatinib and measured cell
viability after 72
hntit'S tsiillt PI/7AAD flow cytometry.
Twenty four primary CLL samples were treated with cerdulatinib, &dual SYK/JAK
inhibitor in the presence or absence of 1L-4/CD40L and apoptosis assessed
using propidium
iodide/Annexin V staining and PAK' cleavage. The effect of cerdulatinib on B
cell receptor and
cytokine receptor induced Signalling was assessed by imMunoblcitting and flow
cytometry.
=CLL cells from 24 patients were treated with cerdulatinib for 24, 48 and 72
hours and
viability assessed using propidium iodide and Annexin V staining. Cenlulatinib
induced
4.:.:q*o*isin i0000entration and t1ote 4;legendent roamer.
Untnutated IGHV and high expreSsion of CD49d are associated with progressive
disease
and a worse prognosis in CLL Importantly for therapeutic us; cerdulatinib
induced significantly
greater apoptosis in U-CLL compared to M-CLI, and in CLL cells with high CD49d
or ZAP70
expression (>30%).comparedto CLL cells with low CD49d or ZAP70 expression
(<30%).
Treatment of CII, cells with ,eaditittinib was found to- induce
cleavage/activation of the
pro-apoptotiecaspase 3 protein and its increased levels of the 85 kDa PARP
sub-fragment, a
marker of apoptosis. Cerdulatinib induced apoptosis was inhibited by co-
treatment with the
caspase inhibitor ZVAD, indicating that cerdulatinib induced apoptosis of CLL
cells occurs via A
caspase dependent mechanism. In addition, levels of the pro-apoptotic protein
NOXA were
increased after 24 hours of cerdulatinib treatment in the presence of ZVAIX
Whilst llle anti-
apoptotic protein MCL1 was decreased.
Ligation of the BCR in lymph nodes enhances CLL survival and resistance to
chemotherapy. Cerdulatinib pre-treatment was able to inhibit both soluble anti-
IgM and
immobilised anti-IgM induced signalling pathways, IL-4 signals via the
JAK/STAT-6 pathway
28
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
ifl,CTL-OCUS and has been shown to be important in mediating protection from
chemotherapy.
TAW:Melt. OfeLL cells with cerdulatinib abrogated IL-4 induced STAT6
phosphorylation. In
addition, cerdulatinib inhibited rt.,-4 increased surface IgM expression after
24 hours lathe
presence of ZVAD.
In patients, lymph node tissue sites provide various signals which protect CLL
cells from
apoptosis. We have therefore used IL-4 and CD4OL to mimic the lymph node
environment in
vitro. 1L-4/CD4OL treatment after 24 hours increased the viability of CLL
cells compared to non-
treated cells.
This Example shows that treatment of primary human CLL cells with cerdulatinib
induced caspase dependent apoptosis, with:increased poteney in CLL samples
poor prognostic
markers; cerdulatinib overcame BCR and IL-4 mediated signalling at
concentratimis achievable
in patients (72.211M) and cerdulatinib induced apoptosis in the presence or
absence of IL-
4/CD4OL support.
Cerduladnib in 60 CLL samples
In 60 CLL samples analyzed according to the methods described above, IC50 in
60 CLL
ranged from 037 to 10.02 M. The average 1050 of cerdulatinib for the cohort
was 2.57 M,
which is clinically achievable.
Whether cell killing by cerdulatinib differs among CLL subgroups stratified by
known
prognostic factors was also studied. It was found that CLL cells with
unmutated 1611V (14.33)
versus mutated IGHV (N=27) have lower 1050s and thus were more sensitive to
cerdulatinib
(P:).0395) (data analyzed with Student Test) (Figure 6). CLL cells with high-
risk genetic
abnormalities (including 'del (114), trisonly 12, and del(17p)) were also more
sensitive ID
cerdulatinib than those vatit (134) or lacking these specific genetic
anomalies altogether
(Figure 7). Thus, CLL cells are sensitive to cerdulatinib, especially in cases
with poor prognosis
=25 by IGHV and cytogenetics.
It is also contemplated that cerdulatinib will also be useful in cases of poor
prognosis as
evidenced by, for example, Zap70.
29
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
Example 3: Clinical and Correlative Results of a Phase I Study of Cerdulatinib
A first-in-human study of cerdulatinib in patients with relapsed/refractory
CLI ALL or'
B-cell non-Hodgkin's lymphoma (NHL) was carried out. A 3+3 dose escalation
study with 28.
day cycles was carried out; the doses studied ranged from 15 mg to 65 mg once
daily and up trt
45 mg twice daily. Patients received a single dose on day 1 for 72 hour PK
evaluation.
Continuous dosing was initiated on day 4.43 patients with CLUSLL or B cell NHL
were
dosed. Median age was 67 years (range 23-85) and median prior therapies (tx)
was 3 (range 1-
8).
Phtumacokinetics ("PK"), pharmacodynamics ("PD"), *and seety were monitored.
Response Was assessed by standard criteria. The level of inhibition of SYK and
JAK was
determined using a variety of whole blood assays measuring signaling via
receptors for the B-
een antigen, IL2, HA, IL6, and GM-CSF. Serum markers of tumor burden,
including CCL3,
CCL4, and other markers of inflammation (r32M and CRP), were also being
measured.
It was observed that PK was suitable for once daily dosing with a half-life of
12-16 hours
and a 2:1 peak-trough ratio. At day 28 of cycle 1, saturating inhibition of
SYK and JAK in
circulating lymphocytes (80-90% inhibition) and serum inflammation markers
(e.g., (32M, CRP,
CCL4; 50-90% inhibition) occurred at plasma concentrations of about 0.6 to 1
AM, achieved at
Cmi,, of the 40 mg dose. At the 65 mg dose, these parameters were 80-90%
inhibited on day 1 of
cycle 1 indicating a more immediate effect compared to lower doses. At the 65
rng dose, steady
state Cruin and C,n0,,, concentrations were approximately 51 and 2 PM,
respectively, sufficient to
induce apoptosis in the majorityOf B cell lymphoma cell lines tested.
In general, cerdulatinib has been well tolerated. Ten total patients have
remained on
cerdulatinib for over 200 days, including 2 who have been on for a year or
more.
Table 4 summarizes data of the steady state pha.rmacokinetics following oral
dosing
where n = 28.
Date Recue/Date Received 2022-11-18
0000100600
V0110010/034061
Table 4, %oily State-01( P011owingOtal Dosing
Dose Croup SS SS SS Cave AUC tau TO
emin Cmax pM .04*Iir
1$ mg/day 0.12:- 0.:18 0.19 iA8
1145'4'
0.04 0.04 0.03 3.9
30 mg/day 0.21 0.63 0.31 7i *IA) 12.3
0.12 0.18 0.12 ' 6.8
40 mg/day 0.87 1.48 11.14 215!
0).8 32.8
0.07 0.15 0.03 = 17.0
45 mg/day * 0.82 1.69 1.11 26.6 22.3 -
0.6 0.6 (16 13.9: :1.5
50 tfig/day 090 207 I:311 $.1.36
0.14 0.54 041 9,9$
Twice daily
("RID")
Regimens
15 mg/twice 029 05' 6.391
daily 0.11 0.13 0.11 4,3
20 mg/twice 0.38 0.89 0.52 8,4 '
daily 0.02 0.16 0.09 I
*PK outlier Om.* state,cmax of 0:15.11.114) was.xemoved from the group.
NVUOr:00= 241,14:4.400 group. of4mg1310, ;i.be 1,00040twa$ obseve4; çj
0,.6 = 216. -401.1.kM; Cob 1..4 Atit toti =3a3 ,4.7K,9; gwittlyz-
k2i5,1*.,
It wasAlserve4 that matAptajnhibitipaprOCXsignaling waa Obspxygd *who)* hipp0
flop FL pat:tot tillowino ONO:Wm; 4000 eaulaaawil:
Table $ Mit Mita**PXIPD dal WItOttl 7-- 43.
31
Date Recue/Date Received 2022-11-18
0001019640
1P0.0201031001
Table 5,1q00 Of DoseratiPs
--Dose SS SS = SS Cave AUC tau I'm % mb % bah. 1L4
Group Cmin (max 14M optir he 11C1 (C494-
C404;)
p111 pM (cniu-Cow4)
Extrapolated from PICIPD,
fit of all data
15 0.12 0.8! (lit) 11,5
0.8 55% 1642%
mg/day 0.04 0.04 0.03 3.9
30 0.21 0.63 12.3 +
114 0 31 -.8.3* 26-
.mg/day 0.12 0.18 0.12 = 6.8 " ' =
40 087 148 111 _01%2 32.8 +
mg/dab 0.07 0.15 0.03 17.0
45 0.82 1.69 1.11 26.6* 22.3
mg/day 0.6 0.6 0.6 13.9 15.5 .
- 92- 100% 63- IS%
50 079 157 099 238 39.0+ "
mg/day 0.37 0.94 0.62 144 12.4
65 p76 1.67 I 1.01 : A 7 251
.mg/day , 0.04 ' 009 ,0,03 "
100
IngidaYQ.$7 ta 8T6i:3 14.4 0:7% nril
patient)
0.29 053 0.39 11.2
IPPAVVICe ct 0. 4.7 1.3 ,:ita 42.-
74% 34 - 51%,
daily
mg/twice 0.02 0.16 0.09 6;2* 55-95%
42-66%
daily
45 1õ.48 1,8 I.
tng/tw iee 100 -
1:00% 95- 95%
daily 0-3',1 01 0.45
MOP* a tbe 40400:4118 :OP 0440440 mop *At *to MAt( and Owl;
OftoontottiOs.ataitaACOM 0.41 iamd 1,63 (L5604,,:te-spooagly..*a the
aYeraSO stead
3 ittite; (SS) 0014000enteatinti vs fain:4141)e 1 Al *0444001, %
liftbibitibit Of Bat (Cita -
wit92; % iva4 63: - 7.8%, QD:deSing
of40400.
32.
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
mg resulted in 50 to 100% (steady-state Cmin to Com) inhibition of SYK and JAK
signaling in
peripheral blood, and significant inhibition of serum matters of inflammation.
Based on these results, it is contemplated that a daily dose of 10 myto about
75 mg of
cerdulatinib is useful for the treatment of hematological cancers in patients
in need thereof.
The extent of inhibition of SYK and JAK signaling as well as inhibition of
serum
markers of inflammation significantly correlated with tumor response. While
the PK is suitable
for QD dosing with a t1/2 of 12-16 hours and a 2:1 peak-trough ratio, it is
contemplated that the
pH-dependent low solubility limited dissolution, and physiologic modeling
suggested that BID
dosing would increase overall expOSnre.
This was accomplished with the 45 mg BID dose, where complete inhibition of
SYK and
JAK at SS Con in peripheral blood assays was observed, consistent with an
approximate
doubling in exposure. At the 45 mg BID dose, SS Con was increased to about 1.5
pM, a
concentration sufficient to induce apoptosis in pre-clinical tumor models
using both primary cells
and cell lines. Subsequent evaluation of 45 mg BID doses in patients
demonstrated higher Con,
Cmak, and AUC values for all patients treated at this dose level. and PD
markers indicated
complete inhibition of both pathways.
Treatment emergent adverse events ("AEs") of grade 3 deemed related to study
and
occurring in 2r more patients were: fatigue (n=5), anemia and neutropenia (n=3
each), and
abdominal pain, neutrophil count decrease, and pneumonia (n=2 each). The
highest overall
exposure Was achieved at the 45 rag BID dose, in which 2 dose limiting
toxcities ("DLTs")
occurred: grade 3 pancreatitis and grade 3 fatigue.
Based on the PK/AE profile, there appeared to be higher grades of adverse
events at SS
Con of 1.25-1.5 pM or grafter. PK modeling indicated a dose of 35 mg BID would
yield a SS
Con of 1.02 pM, SS Coax of 1.3 WI, SS Cave of 1.2 M, 100 ¨ 100% of %
Inhibition of BCR
(Con_ Ctn.), and 90¨ 95% of % Inhibition of HA (Con_ C.), which is predicted
to be
tolerable, efficacious, and provide consistent anti-tumor activity.
Consistent tumor responses were observed in relapsed/refractory CLL and FL
patients
with SS Cmin of 0.7 M.
33
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
Partial responses were observed in 5 heavily pretreated patients with CLL, FL,
and
transformed DLBCL, at doses ranging from 30-65 mg OD. Two partial responses
were observed
in the 45 mg BID dose group, one in a patient with FL and another with CLL.
Responses
typically occurred after 2 cycles of treatment. Multiple patients have
demonstrated nodal
reductions and maintained clinical benefit for over a year.
Conclusions
Cerdulatinib has been well-tolerated in subjects with lymphoid malignancies.
Cerdulatinib demonstrated a favorable PK profile and good tolerability at high
levels of SYK and
JAK inhibition. PK data supported once daily dosing, mainOining substantial
inhibitiOn attmin.
Dose-dependent and selective inhibition of SYK/JAK signaling with maximal
inhibition was
greater than 80 percent; no inhibition of JAK2 or PKC detected. BCR signaling
pathway was 90-
100% inhibited at steady state Cmin/Cowõ JAK/STAT signaling is inhibited 6040%
C6,,/Cmax. PK
data indicated a plateau of exposure from 40 mg to 100 mg oral once daily,
resulting in sub-
micromolar exposure (about 0.7 pM) at stead-state Cõ,i,õ. his contemplated
that solubility may be
the reason. BID closingovercomes this plateau in exposure and has enhanced PD
effects.
Cerdulatinib significantly reduced multiple serum proteins in blood that are
markers of
inflammation, such as 02M, CRP, TNFR, and CCL3/4. Significant correlations
were observed
between tumor response and inhibition of serum markers of inflammation (e.g.
132M and CCL4).
Cerdulatinib has promising activity in heavily pre-treated patients. These
data
deinonstrated evidence of clinical activity in this study of patients with
relapsed/refractory B-cell
malignancies. To date, partial responses have been observed, including in
patients with CLL, FL,
and DLBCL. Tumor reductions were seen in multiple patients, including those
whose disease
progressed on (or who could not tolerate) other BCR pathway inhibitors.
Evidenceof
lymophocytosis was observed as seen with other BCR pathway inhibitors. Results
also showed
that cerdulatinib was well tolerated in these heavily pre-treated patients.
These results, including partial responses, provide additional evidence that
cerdulatinib is
active and well tolerated in patients with relapsed or refractory hematologic
cancers.
34
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
Example 4: Cerdulatinib was found to block proliferation of ibrutinib-
sensitive and
ibrutinib-resistant primary CLL cells and BTKcals transfected cell lines.
Ibrutinib was purchased from Selleckchcm (Houston, TX, USA).
Cell isolation and culture: CLL cells were purified using the Human B cell
Enrichment
Cocktail Kit (Stemcell Technologies, Vancouver, BC, Canada) and were stained
with anti-
CD5/CD19 (Clone HIB 19 and UCHT2, respectively, eBioscience, San Diego, CA)
for
verification of the purity, which was greater than 95% for all cases. Isolated
CLL cells were
cultured in RPMI-1640 with 15% fetal bovine serum (Gibco, Grand Island, NY),
penicillin
(100 IU), and streptomycin (100 P1/110. Ili a density of lx 107 cells/mL in
the presence or
absence of 2.5 tng/mL CpG (01)N2006, stimulatory CpG-ODN type B, human
specific,
purchased from Invivogen (San Diego, CA)), 100 tig/mL CD4OL (Enzo Life
Sciences, Plymouth
Meeting, PA), 10 ng/mL IL-4 =CD4OL (Iiiizo Life Sciences, Plymouth Meeting,
PA). Anti-IgM
stimulation was conducted with plate-bound anti-IgM (10 itg/mL).
Cell proliferation assays: Bromodeoxyuridine (BrdU) was added at the 8-day
culture with
combined stimulatiOn (2.5 Ltg/naL CpG, 100 Wird, CD401,, 10 ng/mL IL-4 and 10
pe/mL plate-
bound anti-IgM). The percentage of BrdU + cells was analyzed by flow cytometry
using the
BrdU Flow kit (BD Biosciences) according to the manufacturer's instructions.
Generation of BTK C481S and T316A mutant cOottructs: BTK wild 'type (WT) cDNA
clone in pCMV6 expression vector was purchased from ORIGFNE (Rockville, MD
USA).
BTKc481s and BTKT316A mutant vectors were generated using the QuikChange.11
Sibp,Directed
Mutagenesis Kit (Agilent Technologies, Cedar Creek, TX, USA) fcalowins
nunnfaeturer's
instructions. The identity of the mutant constructs was confirmed* ganger
sequencing.
Cell transfection, cell count and viability assay: TMD8 cells were transfected
with
constructs of WT BTK or BTKe4815 mutants using kit V, Program U43 on Amaxa
Nucleofector,
=25 according to the manufacturer's protocols (Amaxa, Cologne, Germany).
After transfection, the
cells were co-cultured with NKTert cells in a 24-well plate for 24 hrs for
recovery. Ibrutinib,
oerdulatinib and vehicle (DMSO) were then added into the trandectecl I'MDS
cells and cellular
Date Recue/Date Received 2022-11-18
WO 2016/196385
PCT/US2016/034861
viability, was determined with Museml Count & Viability kit using Muse Cell
Analyzer
(Millipore, Hayward, CA, USA).
Flow cytometry: Cell staining for FACS analysis was done with an optimized
amountof
fluorochroute conjugated mAbs as described previously (e.g. Cheng et al.,
Leukemia.
2014;28():649-657). Briefly, after Washing twice'with Washing buffer (1xPBS,
0.5% BSA,
0.1% NANA 1,,X 106 cells were suspended in 100 pi, washing buffer and stained
with
fluortichreithe conjugated mAbs and incubated for 20 min at room temperature.
Cells were
washed twice in Perrn/Wash buffer befbre scanning by flow cytometer. For
intracellular
phosphoflow analysis, freshly isolated CLL cells were immediately fixed with 2-
4% paraformaldehyde and stored at 80 C, The cryopreserve,d cells were thawed
at roorn
temperature and permeated with 50% methanol on ice for 4 h. 1x106 cells were
suspended in 100
aL washing buffer and stained with tluorochrome Conjugated mAbs and incubated
for 20 min at
room temperature. Flow cytometry was then conducted with LSR2 flow cytcnneter
(BD
Biosciences), and the data were analyzed using the Flowlo software (FLOWJO
LLC, Ashland,
OR, USA).
Primary cells isolated prior to ibrutinib therapy from patients who responded
to ibrutinib
were treated with either 250 n1V1 of ibrutinib or cerdulatinib under the
condition of combined
stimulation. BrdU Incorporation was measured at day 8. These cells responded
equally well to
either drug at this concentration.
Similar experiments on cells iSolated from three ibrutinib-relapsed patients
were also
performed. These samples carry BTK mutations that confer ibrutinib resistance.
Two of the
patients had the known mutation BTK 181s, and one other patient had BTKT3I6A.
Live cell
number was counted daily for 7 days.
When these mutated cells were tested against ibrutinib and cerdulatinib, a
significant
number of BrdLr CLL cells remained following ibrutinib treatment, whereas
cerdulatinib almost
completely bitteked the appearance of BrdU+ cell populations in all three
cases. These
experiments demonstrate that cerdulatinib not only blocks cell proliferation
in ibrutirdb-sensitive
but also ibrutinib-resistant CLL cells.
36
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
To test whether cerdulatinib directly suppresses the growth of ibrutinib-
resistant cells,
both BTKc4818 and wild type BTK (WT) expression vectors were constructed,
cloned, and then
transfected into the ibrutinib-sensitive lymphoma. TMD8. Cell growth
following
exposure to ibrutinib or cerdulatinib was assessed.
It was observed that the growth of WT fiTK -tranafecte,d TM.D8 cells was
similarly
inhibited by both ibrutinib and cerdulatinib at 250 nM (ilgure 4). However,
BTKc4815-
transfected cells were less sensitive to ibrutinib, as expected (Figure 5).
Meanwhile, growth of
these cells was effectively blocked by cerdulatinib. similar to the block
observed in WT BTK
cells.
Example 5: Case studies for patients with follicular lymphoma
CASE STUDY 1 (Patient 1): The patient was a 71 year old Caucasian female with
transformed follicular 3B lymphome (MYC/BCL2/BCL6 positive by IBC). The tumor
was
CD201-, CD10-, ECU (strong), cMYC (50%), and Ki67 (80%).
The patient's prior therapies included: R-CHOP (Rituximab; Cyclophosphamicle;
Doxorubicin hydrochloride; Oneovin; Prednisone) (November 2013-February 2014).
The patient
relapsed in February 2015. The patient began cerdulatinib 65 mg by mouth once
daily ("PO
QD") in March 2015.
The following was, observed: Steady state Cmin-C. was 0.73-1.74 M; %
Inhibition
I1CR signaling was 100%; % Inhibition IL2, 1L4, 1L6 signaling was 60-100%; and
% Inhibition
GM-CSF was ¨20%. The patient showed partial itsponse to cerdulatinib (69%)
after 2 cycles.
Patient 1 progressed in August 2015. Patient 1 relapseitbliowing 5 qyeles--of
therapy.
CASE STUDY 2 (Patient 2): The patient was a 71 year old Caucasian female with
Follicular Lymphoma.
The patient's prior therapies included: Chlorambueil (1998; CR),
Fludarabine/Rituxan
(1999-2000; CR), and Avastin/Rituxan (March 2011-January 2012). Patient 2
relapsed in
September 2014. Patient 2 began cerdulatinib 45 rng PO QD in October 2014, and
the dose
reduced to 30 mg due to fatigue.
37
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
The following was observed: Steady state was 0.2543.6314M. %
Inhibition BCR
signaling; 90% for pSYK Y525/525, 0% for pERK Y204; % Inhibition IL2, HA, IL6
signaling
was 60-100%; % Inhibition GM-CSF was 0%; partial response to cerdulatinib
(56%) after 2
cycles and 76% nodal reduction after one year on therapy.
Patient 2 remains on the drag.
CASE STUDY 3 (Patient 3): The patient was a 79 year old Caucasian male with
Follicular Lymphoma. The patient's tumor bears a SMA mutation in STAT.
The patient's prior therapies: R-CVP (Rituximab; Cyclophosphamide;
Vincristine;
1Prednisolone) (2006-2007), R-rnaintenance (2006-2008), BR (Bendamustine;
Rituximab)
(5/2013-9/2013), Ibrutinib (10/2013-4/2014), R-CHOP (12/2013-4/2014). Patient
3 relapsed in
May 2014. Patient 3 was given cerdulatinib 15 mg by mouth twice daily ("PO
BID") June 2014.
Stable disease was observed in Patient 3 for 6 months on cerdulatinib (20%,
nodal reduction).
These case studies show that cerdulatinih has been well-tolerated:Ito date and
has
promising activity in heavily pre-treated patients having follicular lymphoma.
Responses have
been seen in other Non-Hodgkin's Lymphomas (NI-IL).
* * *
Unless otherwise defined, all technical and seientitte terms used herein have
the same
meaning as commonly understood by one of ordinary skill in the art to which
this invention
belongs.
The inventions illustratively described herein may suitably be practiced in
the absence of
any element or elements, limitation or limitations, not specifically disclosed
herein. Thus, for
example, the terms "comprising", "including," "containing", etc. shall he read
expansively and
without limitation. Additionally, the terms and expressions employed herein
have been used at
terms of description and not of limitation, and there is no intention in the
use of such terms and
expressions of excluding any equivalents of the features shown and described
or portions thereof,
but it is recognized that various modifications are possible within the scope
of the invention
claimed.
38
Date Recue/Date Received 2022-11-18
WO 2016/196385 PCT/US2016/034861
Thus, it should be understood that although the present invention has been
specifically
disclosed by preferred embodiments and optional features, modification,
improvement and
variation of the inventions embodied therein herein disclosed may be resorted
to by these skilled
in the art, and that such modifications, improvements and variations are
considered to be within
the scope of this invention. The materials, methods, and examples provided
here are
representative of preferred embodiments, arc exemplary, and are not intended
as limitations on
the scope of the invention.
The invention has been described broadly and generically herein. Each of the
narrower
species and subgeneric groupings falling within the generic disclosure also
form part of the
invention. This includes the generic description of the invention with a
proviso or negative
limitation removing any subject matter from the genus, regardless of whether
or not the excised
material is specifically recited herein.
In addition, where features or aspects of the invention arc described in terms
of Marlcush
groups, those skilled in the art will recognize that the invention is also
thereby described in terms
of any individual member or subgroup of members of the Markush group.
It is to be understood that while the disclosure has been described in
conjunction with the above
embodiments, that the foregoing description and examples are intended to
illustrate and not limit
the scope of the disclosure. Other aspects, advantages and modifications
within the scope of the
disclosure will be apparent to those skilled in the art to which the
disclosure pertains.
39
Date Recue/Date Received 2022-11-18
